Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$520,000 |
 |
Gilead SciencesGILD |
-$1.76B |
 |
Anavex Life SciencesAVXL |
-$6.3M |
 |
Editas MedicineEDIT |
-$14M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Grygiel Nancy A. | Nov 20, 2025 | Sell | 1,639 | $337.2625 | $550,000 |
| Grygiel Nancy A. | Nov 20, 2025 | Sell | 1,500 | $337.2625 | $510,000 |
| Khosla Rachna | Nov 12, 2025 | Sell | 890 | $336.2422 | $300,000 |
| Gordon Murdo | Nov 12, 2025 | Sell | 6,879 | $336.8326 | $2.3M |
| Grygiel Nancy A. | Aug 20, 2025 | Sell | 1,267 | $296.985 | $380,000 |
| Khosla Rachna | Jun 5, 2025 | Sell | 1,500 | $289.68 | $430,000 |
| Busch Matthew C. | May 2, 2025 | Sell | 1,000 | $279.69 | $280,000 |
| REESE DAVID M | Feb 21, 2025 | Sell | 25,225 | $304.441 | $7.7M |
| Santos Esteban | Feb 19, 2025 | Sell | 8,711 | $292.837 | $2.6M |
| REESE DAVID M | Feb 19, 2025 | Sell | 8,711 | $293.2182 | $2.6M |
| Miller Derek | Feb 19, 2025 | Sell | 1,524 | $293.7367 | $450,000 |
| Miller Derek | Feb 18, 2025 | Sell | 500 | $292.5584 | $150,000 |
| Gordon Murdo | Feb 11, 2025 | Sell | 8,771 | $294.7947 | $2.6M |
| Graham Jonathan P | Feb 7, 2025 | Sell | 25,045 | $293.1173 | $7.3M |
| Grygiel Nancy A. | Feb 5, 2025 | Sell | 1,589 | $304.4731 | $480,000 |
| Grygiel Nancy A. | May 3, 2024 | Sell | 2,117 | $313.0853 | $660,000 |
FAQ - Insider Transactions
The most recent insider transaction for Amgen was conducted by Grygiel Nancy A., who sold 1,639 shares on November 20, 2025 at a price of $337.26 per share.
REESE DAVID M has sold the most AMGN stock in the last 2 years, with a total value of $10M.
The total value of insider transactions for Amgen in the last 2 years is negative, amounting to -$29M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Amgen have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
